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Objective: Despite its use was abandoned several decades ago, the polycationic peptide
colistin has become the last hope to treat severe infections caused by multidrug-resistant
Gram-negative bacteria. Thus, the development of colistin resistance may seriously compro-
mise the efficacy of treatment. Moreover, colistin has high toxicity being dose dependent.
A potentially effective strategy to avoid resistance may be to combine colistin with other
antimicrobials. This may help in the rescue of old antimicrobials and in reducing toxic
undesired effects.
Methods: Antimicrobial susceptibility determination, efflux machinery function measure-
ments in different conditions and measurement of inhibition of the extrusion by colistin were
performed. Moreover, modifications of anisotropy of the membranes by using fluorescent
dyes was accomplished.
Results: Sub-inhibitory concentrations of colistin have a synergistic effect with several
antimicrobials that act intracellularly (targeting protein synthesis and DNA replication).
This effect was demonstrated through the uptake increases of acridine orange. in
Pseudomonas aeruginosa, Escherichia coli and Acinetobacter baumanii but also in an
intrinsically colistin-resistant species as Serratia marcescens. Measurements of the aniso-
tropy of bacterial membranes, as a measure of membrane fluidity, showed significant changes
indicative of colistin activity.
Conclusion: The alterations in the cellular effluxmachinery that resulted in higher intracellular
concentrations of acridine orange, and likely of other antimicrobials combined with data of
membrane fluidity and measured synergism in vitro allow us to envisage the use of these
combinations to fight infections caused by multidrug–resistant bacteria.
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Introduction
In February 2017, the World Health Organization (WHO) published a list of
“critical” resistant bacterial species, including carbapenem-resistant Pseudomonas
aeruginosa, Acinetobacter baumannii, and Escherichia coli. The same document
urged the development of new, alternative treatments and/or new antimicrobials to
reduce the number of deaths caused by multi-drug-resistant (MDR) bacteria.1
The antimicrobial peptide colistin was introduced in 1949 but in the 1980s it was
withdrawn because of its nephrotoxicity and neurotoxicity. However, in the 2000s,
clinicians again turned to colistin in an effort to treat infections caused by MDR Gram-
negative bacteria.2 Colistin is polycationic and interacts with negatively charged mem-
brane components, including lipopolysaccharide (LPS), to disrupt cell membranes. Other
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activities contributing to colistin’s bactericidal effect are ribo-
some binding, alterations of bacterial respiration, disturbances
of the bacterial division, the induction of structural injuries,
and the production of reactive oxygen species.3,4 Nevertheless,
the precise mechanisms of action of colistin and other poly-
myxins are not yet fully understood.
Because the toxicity of colistin is dose-dependent,5
there is considerable interest in strategies that allow dose
reductions while maintaining the therapeutic efficacy of
the drug.6 An additional consideration is the increasing
frequency of colistin-resistant isolates. Among the resis-
tance mechanisms identified thus far are modifications of
LPS (PhoPQ and PmrAB, a two-component regulatory
system) and a transferable mechanism of resistance (mcr-
1).7 The heterogeneous resistance (heteroresistance) of
bacterial populations to colistin has also been described.
However, a previous study suggested that the negative
impact of colistin heteroresistance can be minimized by
co-treatment with other antimicrobial agents.8
Synergism between colistin and other peptide mole-
cules with a wide variety of antimicrobial activities has
been explored. While colistin-carbapenem (β-lactams) is
probably the best-studied combination,9–11 synergies
between colistin and quinolones, fosfomycin, and amino-
glycosides have been reported as well.12 Moreover, even
though Gram-negatives are intrinsically resistant to line-
zolid and glycopeptides, their use in combination with
colistin may be therapeutically promising. In fact,
in vitro synergisms between colistin and linezolid against
A. baumannii clinical strains13 and between colistin and
glycopeptides in a Galleria mellonella model of
infection14 were recently demonstrated. By disrupting the
outer membrane to alter cytoplasmic membrane perme-
ability, colistin allows both linezolid and glycopeptides to
penetrate Gram-negative bacteria, which are otherwise
impervious to these agents. A disturbance of the bacterial
membrane may also underlie the observed synergies
between colistin or colistin-like peptides and other, che-
mically unrelated antimicrobial agents.15 Thus, in this
study we examined the role of colistin synergism with
other antimicrobials with respect to: i) a reduction of the
colistin dose and its impact on the drug’s toxicity and ii)
strategies allowing the avoidance of resistance develop-
ment. Since the chloramphenicol resistance of MDR bac-
teria is mediated by the cellular efflux machinery, the
focus of our study was the effect of colistin on cellular
efflux pumps. Synergy between colistin and chloramphe-
nicol was reported by Abdul Rahim et al.16 Our results
provide evidence of critical alterations in the efflux
machinery of cells exposed to low concentrations of colis-
tin and of the efficacy of other antimicrobials when admi-
nistered in combination with colistin.
Materials and methods
Bacterial strains, culture conditions, and
media
The 24 clinical isolates used in this study differed in their
clinical origins and included 7 strains of MDR
Pseudomonas aeruginosa, 9 strains of MDR Escherichia
coli, and 7 of MDR Acinetobacter baumannii. None of the
strains were epidemiologically related. Pseudomonas aer-
uginosa ATCC 27853 and PAO1, Escherichia coli ATCC
25922, and Acinetobacter baumannii ATCC 17978 served
as control strains. In addition, four strains of Serratia
marcescens (two environmental and two clinical isolates)
were used in the accumulation experiments.
The tryptone soy agar (TSA), tryptone soy broth
(TSB), and Mueller-Hinton broth (MHB) used to culture
the strains were purchased from Sharlau (Sentmenat,
Barcelona, Spain).
Chemicals
Colistin was kindly supplied by Zhejiang Shenghua Biok
Biology Co., Ltd., (Shanghai, China), Chloramphenicol,
amikacin, tetracycline, linezolid, acridine orange, the efflux
pump inhibitor phenyl-arginyl-β-naphthylamide (PaβN),
used in the accumulation assays, and the fluorescent probes
diphenylhexatriene (DPH) and 1-[4-trimethylamino-phenyl]
-6-phenyl-1,3,5-hexatriene (TMA-DPH) were purchased
from Sigma-Aldrich Chemicals (Madrid, Spain). The
LIVE/DEAD® BacLight™ bacterial viability kit was from
Life Technologies (Oregon, USA).
Intracellular accumulation of acridine
orange
Acridine orange (AO: N,N,N’,N’-tetramethylacridine
-3,6-diamine) produces fluorescence after it penetrates
the bacterium and binds to its DNA. It is pumped out
from bacterial cells by at least one efflux pump, as
shown in E. coli17 and other Gram-negative bacteria.18 In
this study, AO uptake was determined: i) under standard
culture conditions, ii) in the presence of the efflux pump
inhibitor PaβN19 (20 µg/ml), and iii) in the presence of
sub-inhibitory concentrations of colistin (0.25 and
0.125 µg/ml).
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The assays were performed in flat-bottomed microtiter
plates, with the same plate used for the three different con-
ditions. Each well contained 100 µl of the bacterial inoculun
and 100 µl of medium. Overnight cultures were diluted in
Ringer’s solution to an optical density (OD) of 1.5 at
520 nm. The inoculated plates were incubated for 1 h,
after which fluorescence was measured in a FLUOstar
OPTIMA Biogen fluorescent microplate reader. The results
were expressed as the percentage increase in fluorescence vs
that in wells containing bacteria and AO (=100%).
Susceptibility test
The microdilution method was used to determine the mini-
mum inhibitory concentrations (MICs) of colistin, chlor-
amphenicol, tetracycline, vancomycin, and linezolid in
each of the strains, according to EUCAST recommenda-
tions. Susceptibility was defined following EUCAST defi-
nition of antimicrobial breakpoints.20 The MIC was also
determined in the presence of the efflux pump inhibitor
PaβN. Bacterial susceptibility to several different antimi-
crobials (chloramphenicol, tetracycline, vancomycin, and
linezolid) in the presence of sub-inhibitory concentrations
of colistin was evaluated as well.
Fluorescent live/dead testing
To rule out bacterial death during the accumulation experi-
ment and to show that AO fluorescence was due solely to
an increase in the uptake of the dye, the viability of the
bacteria in the presence of different concentrations of
colistin was determined in a live-dead analysis.
Briefly, 1 ml of bacterial suspension (prepared as
described above for the AO accumulation experiment)
was incubated with colistin and centrifuged for 5 min at
18,000×g and then stained with 100 µl of the Live/Dead
kit solution (LIVE/DEAD® BacLight™). The cells were
subsequently examined by confocal laser scanning micro-
scopy (CLSM) using a ZEISS LSM 880 microscope
equipped with a 488 nm argon laser, 561 nm and 633 nm
diode lasers, and a 63× magnification oil immersion objec-
tive. All experiments were performed in duplicate. CLSM
images were analyzed using the ZEN 2.3 software. The
proportions of living vs dead bacteria were calculated.
Membrane polarization and anisotropy
Bacterial cultures with or without colistin were washed
twice in buffer and then suspended in saline buffer to a final
OD500 of 0.4. After the addition of DPH or TMA-DPH to
a final concentration of 2 μM and 1 μM, respectively, the
cultures were incubated for 15 min at 37 ºC to enhance
incorporation of the probes into the bacterial membranes.
Anisotropy measurements were performed in cells incu-
bated for 1 h in the presence of colistin.
Fluorescence was measured using a SLM-Aminco
8100 spectrofluorometer with a thermal jacketed cuvette
holder. Fluorescence anisotropy (r) was calculated as:
r ¼ IVV  G  IVH
IVV þ 2G  IVH ;G ¼
IVH
IHH
where Iij is the fluorescence intensity measured when the
excitation (i) and emission (j) polarizers are fixed in the
vertical (V) or horizontal (H) position and G is the ratio of
the sensitivities of the detection system for vertically and
horizontally polarized light. Samples fluorescence emis-
sion was measured at 37 °C using excitation and emission
wavelengths of 381 nm and 426 nm, respectively.21
Results
Susceptibility testing
The MICs for the antimicrobials investigated in this study
are shown in Table 1. All tested strains were susceptible to
colistin according to the breakpoint defined by EUCAST.
Table 1 also shows the effect of sub-inhibitory concentra-
tions of colistin on the MICs of other antimicrobials. The
activities of all antimicrobials tested increased when used
in combination with colistin at ½ of its MIC. The greatest
reduction in the MICs of these drugs was obtained in
A. baumannii, with moderate reductions determined in
P. aeruginosa and E. coli. No significant deviations were
measured in the different series of experiments.
Acridine orange accumulation
Acridine orange penetrates Gram-negative bacteria easily,
although it is normally expelled by efflux pumps located
in the bacterial membrane.22 However, as shown in
Figure 1A–C, in the presence of PaβN, an efflux pump
inhibitor, the uptake of AO increased by nearly 200% in
E. coli and by ~170% in P. aeruginosa and A. baumannii.
Similar effects were achieved with sub-inhibitory concen-
trations of colistin (0.25 µg/ml), which increased AO
uptake in E. coli by ~160%, in P. aeruginosa by 140%,
and in A. baumannii by >125%. The accumulation of AO
was concentration-dependent, at least at the colistin con-
centrations tested (0.125 and 0.25 µg/ml). Moreover, low
concentrations of colistin also increased AO accumula-
tion by Serratia marcescens, a bacterium intrinsically
resistant to colistin (Figure 1D). Accumulation values
Dovepress Armengol et al
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obtained were highly repetitive. In Figure 1 standard
deviations are represented.
To rule out that these results reflected differences in
bacterial viability, a live/dead assay was conducted and the
results were evaluated by CLSM (Figure 2). Bacterial
death in the presence of colistin was ~6%, the same as in
the control (without colistin). Thus, at the tested sub-
inhibitory concentrations, the membrane effects of colistin
did not cause a reduction in cell viability. In addition,
propidium iodide was unable to penetrate the colistin-
treated bacteria.
Membrane polarization
Anisotropy is the inverse of microviscosity. It can be
measured in membranes using the hydrophobic probe
DPH, which enters the inner domain of the lipid bilayer
and becomes lodged parallel to the hydrocarbon chain
axis of the phospholipids but also in the centre of the
bilayer, parallel to the surface. Trimethylammonium
(TMA)-DPH, the cationic derivative of DPH, localizes
closer to the external surface of the lipid membrane, as
the cationic TMA substituent acts as a surface anchor.
Table 2 shows the DPH- and TMA-DPH-based aniso-
tropy values in the three tested species of bacteria incu-
bated with 2 and 0.25 µg colistin/ml. In E. coli
MDR208691, a 1 h incubation with colistin reduced
membrane anisotropy, while in P.aeruginosa and
A. baumannii the reductions were lower (see DPH
results in Table 2). Using the TMA_DPH probe, subtle
effects of colistin on the membrane of E. coli and
P. aeruginosa were seen, while in A. baumannii colistin
slightly rigidified the surface of the lipid membrane.
Table 1 Bacterial susceptibility to antimicrobials administered either alone or in combination with colistin at ½ its MIC
Acinetobacter baumannii COL CHL CHL+COL TET TET+COL LZD LZD+COL VAN VAN+COL
ABAU 137 1 64 ≤0.125 >128 1 >256 4 >256 1
ABAU 80 1 64 0.5 >128 1 >256 8 256 2
ABAU 226 1 128 0.5 4 1 >256 16 >256 8
ATCC 17978 1 64 0.5 2 0.25 >256 16 256 4
ABAU 8 1 64 ≤0.125 >128 0.5 >256 16 256 1
ABAU RUH-875 1 >128 0.25 32 0.5 >256 8 128 4
ABAU 176 1 128 0.5 >128 1 >256 16 256 8
ABAU 34 0.5 64 0.5 >128 2 >256 16 >256 2
Pseudomonas aeruginosa
PA 362 0.25 64 4 4 2 >256 64 256 2
PA 350 0.5 8 4 8 4 256 32 128 2
PA 056 0.5 64 2 16 4 >256 32 >256 8
PA 846 0.25 8 4 4 0.5 128 16 128 8
PA O1 0.5 16 2 8 4 >256 32 128 16
PA 023 0.5 8 0.25 16 2 >256 64 >256 8
PA 666 1 128 2 16 2 >256 32 128 16
PA 086 0.5 8 0.5 8 1 >256 64 256 16
ATCC 27853 0.5 64 4 128 1 >256 64 256 8
Escherichia coli.
MDR 211453 0.5 4 4 1 1 256 32 256 8
MDR 39255 0.5 4 1 128 64 256 32 256 8
MDR 208691 0.5 >128 2 >128 32 256 32 256 8
MDR 205119 0.5 64 1 >128 16 128 16 128 16
MDR 246415 1 >128 16 >128 2 256 32 128 8
MDR 239910 1 16 2 128 16 256 16 256 8
MDR 238192 0.5 128 32 >128 32 256 16 256 16
MDR 215482 1 >128 64 >128 16 >256 8 >256 4
MDR 213873 1 4 4 128 16 128 64 64 16
ATCC 25922 0.5 1 1 1 0,25 128 16 128 16
Note: MICs are reported in µg/ml.
Abbreviations: COL, colistin; CHL, chloramphenicol; TET, tetracycline; LZD, linezolid; VAN, vancomycin.
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Discussion
Although the toxicity of colistin resulted in the eventual
discontinuation of its use as an antibiotic, with the
emergence of bacterial multi-resistance the drug has
been resurrected for the treatment of infections by
MDR bacteria. However, the re-introduction of colistin
has been accompanied by the appearance of resistance
to colistin and other polymyxins, most commonly via
LPS modification. A further challenge is the heterore-
sistance of bacterial populations; that is, the presence of






















































































































Figure 1 Average acridine orange (AO) accumulation in the presence of the efflux inhibitor PaβN and sub-inhibitory concentrations of colistin. (A–C) colistin-sensitive
strains; (D) a species intrinsically resistant to colistin.
A B C
10µm10µm10µm
Figure 2 Confocal light microscopy imaging after Live/Dead staining of Pseudomonas aeruginosa. (A) Untreated cells; (B) cells treated with colistin at 0.25 μg/mL and (C)
cells treated with colistin at bactericidal concentration. Similar images were obtained for Acinetobacter baumanii and E. coli (not shown). TEM of thin sections of S. marcescens
after treatment with colistin. Blebs formed by the outer membrane are easily visualized.
Dovepress Armengol et al
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To avoid the development of colistin resistance, the
colistin is used in combination with a second antimicrobial
agent, based on the advantage conferred by the main
mechanism of colistin action: membrane permeabilization.
Ritcher et al23 described the increased accumulation of
several antimicrobials in the presence of high concentra-
tions of colistin (6 mM =7 µg/ml). In our study, sub-MIC
concentrations of colistin were used to explore their ability
to enhance the action of other antibiotics while minimizing
the risk posed by colistin toxicity. The results showed that
sub-MIC concentrations of colistin altered the efflux pump
function of the bacterial cells, as evidenced by the increases
in AO accumulation in isolates of E. coli, A. baumannii, and
P. aeruginosa. All the three species are naturally susceptible
to colistin, which at concentrations at or above its MIC
causes catastrophic effects on the outer membrane.
Moreover, similar results were obtained in S. marcescens,
a Gram-negative species that is naturally colistin-resistant.
Specifically, we were able to demonstrate severe alterations
in AO efflux in S. marcescens cells treated with sub-
inhibitory concentrations of colistin. This result suggests
a mechanism of outer membrane injury in Gram-negative
bacteria in which correct formation of the AcrAB-tolC
complex and other efflux-pump-based complexes is pre-
vented and efflux is therefore interrupted.
Diffusion and active transport by efflux systems are
strongly dependent on membrane fluidity.24 Vincent et al25
described changes in membrane polarization in bacterial
cells exposed to tetracycline. As the main mechanism of
action of colistin is membrane disruption, we hypothesized
that concentrations of the drug below the MIC would be
sufficient to alter membrane fluidity. Our results showed
that low concentrations of colistin significantly increased
the fluidity of the inner regions of the lipid bilayers with-
out significantly modifying the more polar regions of the
membrane, as indicated by anisotropy measurements.
These colistin-induced membrane alterations would pre-
sumably i) facilitate the penetration of other antimicrobials
and thus increase their biological activity and ii) decrease
the lateral lipid pressure inside lipid membranes to reduce
local rigidity and modify the correct packing of the efflux
pumps, thus altering the efflux of drugs reaching the cell,
as observed in Figure 1.
Using a live/dead assay, we showed that, at 1/2 its
MIC, colistin did not cause bacterial death or injury to
the cytoplasmic membrane, as the amount of propidium
iodide and thus the proportion of living bacteria were
identical in colistin-treated and untreated (control) cells.
Therefore, the above-described results cannot be explained
by differences in bacterial viability.
The cellular accumulation of AO increases in the pre-
sence of the efflux pump inhibitor PaβN since the dye is
normally pumped out by efflux systems. Sub-inhibitory
concentrations of colistin also led to increases in the amount
of AO retained by the bacteria. Given the results of the live/
dead test, the observed accumulation of AO can be attributed
to the disruption of membrane permeability by colistin and
to the indirect inhibition of the cellular efflux machinery.
We then demonstrated that sub-inhibitory concentra-
tions of colistin increase the activity of antimicrobials
whose mechanisms of resistance are associated with efflux
systems and/or decreased permeability (Table 1). The
synergy between clinically relevant concentrations of
colistin and chloramphenicol in Klebsiella pneumoniae16
as well as between colistin and colistin-like peptides and
carbapenems in imipenem-resistant P. aeruginosa15 has
Table 2 Changes in membrane fluidity (anisotropy) in the presence of colistin
Colistin (μg/ml) Anisotropy (r)
DPH TMA-DPH
E. coli 0 0.2787±0.0219 0.267±0.039
0.25 0.26986±0.020 0.265±0.028
2.00 0.2488±0.009 0.2681±0.0212
P. aeruginosa 0 0.3139±0.034 0.284±0.0247
0.25 0.3105±0.0359 0.274±0.0199
2.00 0.2877±0.0213 0.273±0.0212
A. baumannii 0 0.314±0.027 0.255±0.005
0.25 0.306±0.029 0.260±0.0081
2.00 0.307±0.0025 0.260±0.006
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been reported. An enhancement of the activity of glyco-
peptides targeting A. baumannii was also shown in vivo, in
the moth Galleria mellonella, in which colistin increased
the antimicrobial activity of vancomycin by up to
90%.14,26 Moreover, Liu et al13 reported the efficacy of
anti-Gram-positive antimicrobials in the treatment of
A. baumannii infections when these drugs were adminis-
tered together with colistin. During the writing of the
present article, Brennan-Krohn et al27 published a study
demonstrating the synergism of colistin and a wide range
of antimicrobials in both colistin-susceptible and colistin-
resistant Enterobacteriaceae. The authors attributed these
results to the direct effect of colistin on the bacterial outer
membrane. Almost simultaneously, Fang et al28 reported
similar data in tests of E. coli exposed to combinations of
colistin and either azithromycin or rifampin, both in vitro
and in vivo. Our data provide additional, biophysical evi-
dence supporting those observations. Furthermore, these
results together suggest lines of further research aimed at
the development of compounds that, while unable to kill
bacteria themselves, significantly alter bacterial membrane
fluidity and thus potentiate the activity of traditional
antimicrobials.
In summary, our study showed that, by altering the
permeability of the outer membrane of Gram-negative
bacteria, colistin acts synergistically with a broad spectrum
of antimicrobials. The mechanism of action involves mod-
ification of membrane fluidity as well as the direct partial
inhibition of efflux pump function.
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